Udenyca
Payments companies reported to CMS as associated with Udenyca. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Udenyca, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Udenyca
These are the largest totals companies reported as associated with Udenyca. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Marjorie Hein | Duarte, CA | Family | $4,170.00 |
| Ruemu Birhiray | Indianapolis, IN | Hematology & Oncology | $2,843.05 |
| Kathleen Clifford | Boise, ID | Nurse Practitioner | $2,392.00 |
| Maria Theodoulou | Albany, NY | Medical Oncology | $1,929.86 |
| Patricia Rich | Atlanta, GA | Medical Oncology | $1,632.00 |
| Francis Arena | Lake Success, NY | Hematology & Oncology | $1,604.94 |
| Raja Mudad | Miami, FL | Hematology & Oncology | $1,111.96 |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $864.42 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $857.91 |
| Alaa Owainati | Pontiac, MI | Hematology & Oncology | $592.14 |
Prescribed Udenyca?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.